OVERVIEW

Dry Eye Disease: Therapeutic Updates and Optimizing Treatment is organized by ScientiaCME.

Dates:
Release Date: July 30, 2019
Expiration Date: July 30, 2021

Accreditation:
Credit Designation: ScientiaCME designates this educational activity for a maximum of 1.0 AMA PRA Category 1 Credit(s)™ toward the AMA Physician's Recognition Award. Physicians should only claim credit commensurate with the extent of their participation in the activity.

Pharmacists:
ScientiaCME is accredited by the Accreditation Council for Pharmacy Education (ACPE) as a provider of continuing pharmaceutical education. This program is approved for 1.0 hours (0.1 CEUs) of continuing education. Proof of participation will be posted to your NABP CPE profile within 4 to 6 weeks to participants who have successfully completed the post-test. Participants must participate in the entire presentation and complete the course evaluation to receive continuing pharmacy education credit. ACPE # 0574-0000-19-030-H01-P. ACPE Accreditation effective 08/17/19 expires 08/17/21.

Description:
In this online CME self-learning activity:
Dry eye disease (“dry eye”), also referred to as ocular surface disease and keratoconjunctivitis sicca, is a condition with a diverse group of etiologies and clinical presentations. Common symptoms include discomfort or pain, visual disturbance, and tear film instability. Compared with those without the condition, patients with dry eye experience higher rates of lost of work productivity, impaired of daily activities, medical visits, and sleep and mood disorders, and worse emotion well-being and overall quality of life. Although dry eye prevalence varies based on a variety of patient factors, estimates place the prevalence of dry eye as high as 19% of the adult population and more than 34% of the elderly population.

Due to the widespread impact of dry eye, it has been termed a “modern epidemic,” yet current clinical practice in terms of understanding, diagnosing, and managing dry eye is suboptimal, representing a potential gap in care. Dry eye is both underdiagnosed and undertreated.

Objectives:
By the end of the session the participant will be able to:
• Describe the pathophysiology of dry eye with a focus on the factors affecting therapeutic mechanisms.
• Identify symptoms of dry eye and optimize diagnostic procedures to initiate treatment as early as possible.
• Accurately diagnose,** discuss, and apply treatment strategies in dry eye
• Evaluate available and emerging therapeutic options for dry eye, and individualize patient treatment regimens.